Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactionsJeffry Adiwidjaja, Alan V. Boddy, Andrew J. McLachlan|Expert Opinion on Drug Metabolism & Toxicology|2017Cited by 172
Interactions between natural products and cancer treatments: underlying mechanisms and clinical importanceWai-Jo Jocelin Chan, Joanna Harnett, Jeffry Adiwidjaja et al.|Cancer Chemotherapy and Pharmacology|2023Cited by 58
Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in PaediatricsJeffry Adiwidjaja, Andrew J. McLachlan, Alan V. Boddy|Frontiers in Pharmacology|2020Cited by 44
Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s WortJeffry Adiwidjaja, Andrew J. McLachlan, Alan V. Boddy|Clinical Pharmacokinetics|2019Cited by 30
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APLHarry Iland, Andrew H. Wei, Peter Tan et al.|Blood Advances|2025Cited by 4